# Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00676052** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 576 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK233705 12.5mcg
- **DRUG:** GSK233705 25mcg
- **DRUG:** GSK233705 50mcg
- **DRUG:** GSK233705 100mcg
- **DRUG:** GSK233705 200mcg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00676052
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-16
- **Primary completion:** 2008-12-22
- **Final completion:** 2008-12-22
- **Target enrollment:** 576 (ACTUAL)
- **Last updated:** 2017-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676052, "Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00676052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*